NicOx : Garufi ... e la Rivoluzione Pharma (2 lettori)
- Creatore Discussione Yesod
- Data di Inizio
- Stato
guly
Forumer storico
che ridere questo e' il tuo ultimo post.degno di tesiete già partiti con VIC
attenzione al divieto su NICOX non vogliono più bovini investiti
tradermen
Forumer storico
NicOx Says Naproxcinod Partnership, U.S. Filing May Be Delayed
By Albertina Torsoli
June 18 (Bloomberg) -- NicOx SA said its most advanced experimental drug may get a commercial partner and be submitted to U.S. regulators later than the French drugmaker had planned.
The filing with the Food and Drug Administration “is on track for June, July or August” and “it’s very difficult” to make forecasts on when an agreement with one or more potential partners will be reached, Karl Hanks, a spokesman, said in a telephone interview today.
NicOx, based in Sophia Antipolis on the French Riviera, already has partnerships with Pfizer Inc. and Merck & Co. It’s looking for an established drugmaker to help sell naproxcinod, a painkiller that would be its first approved medicine and may garner annual sales of as much as $1 billion, according to Chief Executive Officer Michele Garufi.
Garufi, who co-founded the company in 1996, said in a Jan. 22 interview he was planning to submit naproxcinod to U.S. regulators by the middle of the year and aimed to have a partner before the end of June.
“Discussions are ongoing,” Hanks said today, declining to identify potential partners. “Things are progressing, there is a definite interest but there is also conservatism in some companies.”
NicOx may end up signing accords with two partners, according to Hanks.
“Some of the companies are interested in the U.S. and others are interested in a European deal,” he said. “We may see more than one deal coming through. That seems logical to us at this point in time.”
NicOx has been trying to show that naproxcinod works as well as the standard painkiller naproxen, sold over the counter as Aleve by Bayer AG, and without side effects such as high blood pressure.
By Albertina Torsoli
June 18 (Bloomberg) -- NicOx SA said its most advanced experimental drug may get a commercial partner and be submitted to U.S. regulators later than the French drugmaker had planned.
The filing with the Food and Drug Administration “is on track for June, July or August” and “it’s very difficult” to make forecasts on when an agreement with one or more potential partners will be reached, Karl Hanks, a spokesman, said in a telephone interview today.
NicOx, based in Sophia Antipolis on the French Riviera, already has partnerships with Pfizer Inc. and Merck & Co. It’s looking for an established drugmaker to help sell naproxcinod, a painkiller that would be its first approved medicine and may garner annual sales of as much as $1 billion, according to Chief Executive Officer Michele Garufi.
Garufi, who co-founded the company in 1996, said in a Jan. 22 interview he was planning to submit naproxcinod to U.S. regulators by the middle of the year and aimed to have a partner before the end of June.
“Discussions are ongoing,” Hanks said today, declining to identify potential partners. “Things are progressing, there is a definite interest but there is also conservatism in some companies.”
NicOx may end up signing accords with two partners, according to Hanks.
“Some of the companies are interested in the U.S. and others are interested in a European deal,” he said. “We may see more than one deal coming through. That seems logical to us at this point in time.”
NicOx has been trying to show that naproxcinod works as well as the standard painkiller naproxen, sold over the counter as Aleve by Bayer AG, and without side effects such as high blood pressure.
socc_2003
Nuovo forumer
Dalla traduzione maccheronica, la notizia mi sembra "leggermente" differente.
Siccome non sono un esperto di rumors la riporto così come copiato ed incollato:
http://www.lavf.com/news-bourse/Nic...endre_pour_le_partenariat-COX-0000080159.html
NICOX : Peut-être encore quelques mois à attendre pour le partenariat
Aujourd'hui à 11:36 Catégorie : Actualité société
(Tradingsat.com) - Les actionnaires de NicOx étaient réunis hier en assemblée générale sur deuxième convocation. L'assemblée générale du 20 mai dernier n'avait en effet pu délibérer valablement faute du quorum requis.
Aucun nom de partenaire potentiel pour la co-commercialisation du naproxcinod, l'anti-inflammmatoire développé par la société de biotechnologie, n'a filtré hier.
Selon un analyste parisien, il faudra d'ailleurs peut-être attendre le troisième, voire le quatrième trimestre pour que ledit partenariat soit annoncé « vu le temps que prennent les discussions, notamment sur la notice du médicament et la volonté de NicOx de ne pas « brader » sa molécule phare ».
Copyright (c) 2006-2009 Tradingsat.com. Tous droits réservés.
Siccome non sono un esperto di rumors la riporto così come copiato ed incollato:
http://www.lavf.com/news-bourse/Nic...endre_pour_le_partenariat-COX-0000080159.html
NICOX : Peut-être encore quelques mois à attendre pour le partenariat
Aujourd'hui à 11:36 Catégorie : Actualité société
(Tradingsat.com) - Les actionnaires de NicOx étaient réunis hier en assemblée générale sur deuxième convocation. L'assemblée générale du 20 mai dernier n'avait en effet pu délibérer valablement faute du quorum requis.
Aucun nom de partenaire potentiel pour la co-commercialisation du naproxcinod, l'anti-inflammmatoire développé par la société de biotechnologie, n'a filtré hier.
Selon un analyste parisien, il faudra d'ailleurs peut-être attendre le troisième, voire le quatrième trimestre pour que ledit partenariat soit annoncé « vu le temps que prennent les discussions, notamment sur la notice du médicament et la volonté de NicOx de ne pas « brader » sa molécule phare ».
Copyright (c) 2006-2009 Tradingsat.com. Tous droits réservés.
- Stato